България - български - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v. - inactivated viral antigens of ibv strain m41, ibv strain 249 g, art strain but1#8544, eds’76 strain bc14, ndv strain clone 30 - инжекционна емулсия - ≥ 5,5 log2 vn единици* ≥ 4,0 log2 vn единици ≥ 9,5 log2 elisa единици * ≥ 6,5 log2 hi единици * ≥ 4,0 log2 hi единици за 1/50та от доза* или съдържащ ≥ 50 pd50 единици - пилета

България - български - БАБХ (Българска агенция по безопасност на храните)

bioveta, a,.s. - inactivated e. coli expressing f5 (k99) adhesin, strain o8:k35; inactivated bovine rotavirus, serotype g6p1, strain tm-91; inactivated bovine coronavirus, strain c-197 - инжекционна суспензия - rp ≥ 1/2 ml - говеда

България - български - БАБХ (Българска агенция по безопасност на храните)

laboratorios syva, s.a. - inactivated erysipelothrix rhusiopathiae, serotype 2, strain se-9; inactivated porcine parvovirus, strain pvp-7 - инжекционна емулсия/ emulsion for injection - 7,4 – 61,0 elisa units, 320 – 5120 hit/ 2 ml - свине

Европейски съюз - български - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - овца - Активна имунизация на овце от 1. На 5-месечна възраст, за предотвратяване на виремии, причинена от вирус катаральной по свинете, овце, серотипы 1 и 8. Начало на имунитета: 21 дни след завършване на схемата на първичната ваксинация. Продължителност на имунитета: 12 месеца.

България - български - БАБХ (Българска агенция по безопасност на храните)

zoetis belgium s.a. - parainfluenza virus 3 (ПИ3); текущ; прецежда се РЛБ 103; респираторно-синцитиальный вирус от едър рогат добитък (БРС), на живо, щам 375; вирусна диария едър рогат добитък (bvdv) тип 1, инактивированной, щам 5960 и прецедете 6309 - лиофилизат и разтворител за инжекционна суспензия - от 10 на степен 5 до 10 на степен 8,6 ccid50; от 10 на степен 5 до 10 на степен 7,2 ccid 50; най-малко 3 log 2 - говеда

Европейски съюз - български - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - Пиле - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Европейски съюз - български - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Ваксини - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.

Европейски съюз - български - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Ваксини - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

България - български - БАБХ (Българска агенция по безопасност на храните)

bioveta, a.s. - Вирус гана, щам ЦДВ био 11/а; кучешки аденовирус тип 2, се прецежда kav-2 био 13; Вид на парвовирус кучета 2б, прецедете cpv-2б био 12/Б; вид на кучешки, parainfluenza virus 2, се прецежда cpiv-2 био 15 - лиофилизат и разтворител за инжекционна суспензия - мин. 10 на 3,1 степен - макс. 10 на 5,1 степен tcid50; мин. 10 на 3,6 степен- макс. 10 на 5,3 степен tcid50; мин. 10 на 4,3 степ - кучета

България - български - БАБХ (Българска агенция по безопасност на храните)

bioveta, a.s. - Вирус гана, щам ЦДВ био 11/а; кучешки аденовирус тип 2, се прецежда kav-2 био 13; Вид на парвовирус кучета 2б, прецедете cpv-2б био 12/Б; вид на кучешки, parainfluenza virus 2, се прецежда cpiv-2 био 15 - лиофилизат и разтворител за инжекционна суспензия - мин. 10 на 3,1 степен - макс. 10 на 5,1 степен tcid50; мин. 10 на 3,6 степен - макс. 10 на 5,3 степен tcid50; мин. 10 на 4,3 сте - кучета